OCT 30 CRDAC

On Thursday, October 30, 2014 the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will discuss new drug application (NDA) 206316, edoxaban tablets, submitted by Daiichi Sankyo, Inc., for the prevention of stroke and systemic embolism (blood clots other than in the head) in patients with nonvalvular atrial fibrillation (A Fib; abnormally rapid and chaotic contractions of the atria, the upper chambers of the heart).

See the Announcement